---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-117219"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:58:51.715725+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rezolute Q1 FY2024 net loss $14.5M; RZ358 Phase 3 start planned before year-end

## Summary
- Net loss of $14.5M for Q1 FY2024 vs $9.8M in same period last year.
- R&D expenses $12.2M (up 58% YoY) due to increased clinical and manufacturing costs.
- Cash and investments $106.9M as of Sep 30, 2023, down from $118.4M at Jun 30, 2023.
- RZ358 granted EMA PRIME designation; Phase 3 sunRIZE study for congenital hyperinsulinism to initiate Q4 2023.
- RZ402 Phase 2 enrollment in diabetic macular edema near completion; update expected before year-end.

## SEC filing metadata
- accession: 0001104659-23-117219
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465923117219/0001104659-23-117219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465923117219/tm2330300d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-117219
- JSON: https://secwatch.observer/filing/0001104659-23-117219.json
- Plain text: https://secwatch.observer/filing/0001104659-23-117219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.